DK0686155T3 - Xanthinderivater som adenosin A1-receptor-antagonister - Google Patents
Xanthinderivater som adenosin A1-receptor-antagonisterInfo
- Publication number
- DK0686155T3 DK0686155T3 DK94910661T DK94910661T DK0686155T3 DK 0686155 T3 DK0686155 T3 DK 0686155T3 DK 94910661 T DK94910661 T DK 94910661T DK 94910661 T DK94910661 T DK 94910661T DK 0686155 T3 DK0686155 T3 DK 0686155T3
- Authority
- DK
- Denmark
- Prior art keywords
- adenosine
- pct
- receptor antagonists
- xanthine derivatives
- sec
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940124258 Adenosine A1 receptor antagonist Drugs 0.000 title 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 | |
| PCT/US1994/001009 WO1994019349A1 (en) | 1993-02-26 | 1994-01-27 | Xanthine derivatives as adenosine a1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0686155T3 true DK0686155T3 (da) | 1999-02-01 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94910661T DK0686155T3 (da) | 1993-02-26 | 1994-01-27 | Xanthinderivater som adenosin A1-receptor-antagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (cs) |
| EP (1) | EP0686155B1 (cs) |
| JP (1) | JPH08512281A (cs) |
| KR (1) | KR100315898B1 (cs) |
| CN (1) | CN1041418C (cs) |
| AT (1) | ATE169019T1 (cs) |
| AU (1) | AU680241B2 (cs) |
| CA (1) | CA2155130C (cs) |
| DE (1) | DE69412073T2 (cs) |
| DK (1) | DK0686155T3 (cs) |
| ES (1) | ES2120025T3 (cs) |
| HU (1) | HUT72677A (cs) |
| IL (1) | IL108750A (cs) |
| MX (1) | MX9401406A (cs) |
| NO (1) | NO311920B1 (cs) |
| NZ (1) | NZ262984A (cs) |
| TW (1) | TW261532B (cs) |
| WO (1) | WO1994019349A1 (cs) |
| ZA (1) | ZA941176B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (en) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| EP2011499A3 (en) | 1998-06-02 | 2010-10-20 | OSI Pharmaceuticals, Inc. | Pyrrolo[2,3d]Pyrimidine compositions and their use |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| BR0215202A (pt) | 2001-12-20 | 2004-10-13 | Osi Pharm Inc | Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso |
| JP2005538950A (ja) * | 2002-05-15 | 2005-12-22 | ジェンザイム、コーポレーション | ２−アルキルシステイン、２−（ヒドロキシル化フェニル）−４−アルキルチアゾリン−４−カルボン酸およびそれらの誘導体の合成 |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| EP1709966A4 (en) * | 2003-12-09 | 2009-04-29 | PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION | |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active Expired - Fee Related
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en not_active Ceased
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69412073D1 (de) | 1998-09-03 |
| ZA941176B (en) | 1994-09-20 |
| HU9502495D0 (en) | 1995-10-30 |
| NO953353L (no) | 1995-08-25 |
| TW261532B (cs) | 1995-11-01 |
| HUT72677A (en) | 1996-05-28 |
| CA2155130C (en) | 1994-09-01 |
| IL108750A0 (en) | 1994-05-30 |
| WO1994019349A1 (en) | 1994-09-01 |
| JPH08512281A (ja) | 1996-12-24 |
| AU680241B2 (en) | 1997-07-24 |
| US5840729A (en) | 1998-11-24 |
| EP0686155B1 (en) | 1998-07-29 |
| NO311920B1 (no) | 2002-02-18 |
| ES2120025T3 (es) | 1998-10-16 |
| KR100315898B1 (ko) | 2002-02-28 |
| NZ262984A (en) | 1997-05-26 |
| NO953353D0 (no) | 1995-08-25 |
| CN1118599A (zh) | 1996-03-13 |
| ATE169019T1 (de) | 1998-08-15 |
| EP0686155A1 (en) | 1995-12-13 |
| CN1041418C (zh) | 1998-12-30 |
| IL108750A (en) | 2000-09-28 |
| MX9401406A (es) | 1994-08-31 |
| DE69412073T2 (de) | 1999-02-18 |
| CA2155130A1 (en) | 1994-09-01 |
| AU6296894A (en) | 1994-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| ES2091689T3 (es) | Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. | |
| DE69611377D1 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| ES2121193T3 (es) | Derivados de bencimidazoles. | |
| NO960630L (no) | Heterocykler anvendelige som neurokinin antagonister | |
| DE69327536D1 (de) | Fibrinogenrezeptor-antagonisten | |
| DK0686155T3 (da) | Xanthinderivater som adenosin A1-receptor-antagonister | |
| TR199900501T2 (xx) | Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�. | |
| ES2134929T3 (es) | Derivados de pirrolo-piridina como ligandos para receptores de dopamina. | |
| NO943133L (no) | Benzodiazepinderivater egnet til bruk som CCK-reseptorantagonister | |
| ES2098510T3 (es) | Antagonista de galanina. | |
| ATE113056T1 (de) | Künstliche rezeptor-analoge. | |
| GR3024854T3 (en) | Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances. | |
| ATE153027T1 (de) | Zuckerderivate von makroliden | |
| PT958290E (pt) | Derivados de 1,4-di-hidropiridina e seu uso em terapia | |
| ES2093515T3 (es) | Aplicacion del riluzol como radio-restaurador. | |
| ATE221068T1 (de) | Anellierte beta-carboline | |
| ITMI950956A0 (it) | Uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca |